Introduction and objectives: In acute myocardial infarction (MI), novel highly deliverable drug-eluting stents (DES) may be particularly valuable as their flexible stent designs might reduce device-induced traumas to culprit lesions. The aim of the study was to assess the safety and efficacy of percutaneous coronary interventions with 2 novel durable polymer-coated DES in patients with acute MI.
Methods: The prospective, randomized DUTCH PEERS (TWENTE II) multicenter trial compares Resolute Integrity and Promus Element stents in 1811 all-comer patients, of whom 817 (45.1%) were treated for ST-segment elevation MI or non—ST-segment elevation MI and the 2-year outcome is available in 99.9%. The primary clinical endpoint is target vessel failure (TVF), a composite of cardiac death, target vessel related MI, or target vessel revascularization.
Results: Of all 817 patients treated for acute MI, 421 (51.5%) were treated with Resolute Integrity and 396 (48.5%) with Promus Element stents. At the 2-year follow-up, the rates of TVF (7.4% vs 6.1%; P =.45), target lesion revascularization (3.1% vs 2.8%; P =.79), and definite stent thrombosis (1.0% vs 0.5%; P =.69) were low for both stent groups. Consistent with these findings in all patients with acute MI, outcomes for the 2 DES were favorable and similar in both, with 370 patients with ST-segment elevation MI (TVF: 5.1% vs 4.9%; P =.81) and 447 patients with non—ST-segment elevation MI (TVF: 9.0% vs 7.5%; P =.56).
Conclusions: Resolute Integrity and Promus Element stents were both safe and efficacious in treating patients with acute MI. The present 2-year follow-up data underline the safety of using these devices in this particular clinical setting. Full English text available from: www.revespcardiol.org/en
|Translated title of the contribution||Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial|
|Number of pages||8|
|Journal||Revista Espanola de Cardiologia|
|Publication status||Published - 1 Dec 2016|
- Acute coronary syndrome
- Cobalt-chromium zotarolimus-eluting stent
- Drug-eluting stent
- DUTCH PEERS (TWENTE II) trial
- Myocardial infarction
- Percutaneous coronary intervention
- Platinum-chromium everolimus-eluting stent
- Promus Element stent
- Resolute Integrity stent